The HLA typing for the transplants market is projected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%. The growth of this market is primarily driven by the increasing number of transplantation procedures, technological advancements in the field of HLA typing, increasing public-private funding for target research activities, and the growing burden of infectious diseases that are driving the growth of the HLA typing for transplants market. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities—especially in emerging markets, which are expected to witness the highest growth.

 Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742

 Key Market Players

Some prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), Care Dx (US), and Immucor, Inc. (US). An analysis of the developments in the HLA typing for the transplants market from 2016–2019 showed that product launches, expansions, agreements, partnerships, collaborations, and acquisitions were the most widely adopted growth strategies in the market.

Thermo Fisher Scientific is the leading player in the global HLA typing for the transplants market. The company has a broad range of automated instruments for antibody screening and analysis, semi-automated systems for serological assays, standalone systems & reagents for molecular and non-molecular assay procedures, including HLA typing products for transplant. The company focuses on launching technologically advanced products to maintain its leadership in the HLA typing for the transplants industry.

Based on the product, the reagents & consumables segment held the largest share of the market in 2019.

Based on the product, the HLA typing for the transplants market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest share of the global HLA typing for the transplants market in 2019. Factors such as the increasing patient emphasis on effective and early patient profiling during organ transplantation and the growing adoption of transplant diagnostic techniques (includes HLA typing) in related research studies are driving the growth of this segment.

Browse in-depth TOC on "HLA Typing for Transplant Market"

141 – Tables

36 – Figures  

193 – Pages

Based on technology, the molecular assays segment is expected to witness the highest growth during the forecast period.

Based on technology, the HLA typing for the transplants market is segmented into molecular assay and non-molecular assay technology. The molecular assay technology segment is expected to register the highest CAGR during the forecast period. Factors such as its varied applications in patient profiling, rising public-private investments to support product development, and increasing clinical evidence of its efficacy are driving the growth of this segment.

Based on the application, the diagnostic application segment accounted for the largest share of this market in 2019.

Based on the application, the HLA typing for the transplants market is categorized into diagnostic and research applications. Diagnostic applications accounted for the largest share of the HLA typing for the transplants market in 2019. Increasing adoption of molecular assay procedures for pathogen detection & histocompatibility testing, and the rising incidence of chronic diseases, and supportive government regulations to increase organ donations across major healthcare markets are the key factors supporting the growth of this application segment.

 

North America accounted for the largest share of the HLA typing for transplants market in 2019

North America accounted for the largest share of the HLA typing for the transplants market in 2019, followed by Europe. This can primarily be attributed to the continuous commercialization of innovative transplant diagnostic products (includes HLA typing) coupled with ongoing advancements in the field of genomics and proteomics, recent discovery genetic biomarkers & their clinical role in immunoassay testing, and the increasing prevalence of chronic and communicable diseases.

Get 10% Customization on this Research Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96374742